Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Palestinians tell BBC they were sexually abused in Israeli prisons - 2Step by step instructions to Pick the Right Sunlight powered charger Type for Your Home
- 3Ukrainian Army Converts E38 BMW 7-Series Into Multiple Rocket Launch Platform
- 4The most effective method to Shake Hands Expertly: A Bit by bit Guide
- 5Discovering a true sense of harmony: Contemplation and Care Practices
- Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- A Time of Careful Eating: Individual Tests in Nourishment
- New trailer for 'Bridgerton' Season 4 teases Benedict's love story: Watch it here
- Instructions to Pick the Right Toothpaste for Your Dental Requirements
- Nutrient Rich Natural products: Lift Your Wellbeing
- Massachusetts court hears arguments in lawsuit alleging Meta designed apps to be addictive to kids
- Study finds humans were making fire 400,000 years ago, far earlier than once thought
- 'Senseless violence' erupts at Christmas tree lighting; 4 injured
- Hilary Duff releases 'Mature,' her 1st song in 10 years
